Literature DB >> 22084247

CUEDC2 (CUE domain-containing 2) and SOCS3 (suppressors of cytokine signaling 3) cooperate to negatively regulate Janus kinase 1/signal transducers and activators of transcription 3 signaling.

Wei-Na Zhang1, Li Wang, Qiong Wang, Xue Luo, Di-Feng Fang, Yuan Chen, Xin Pan, Jiang-Hong Man, Qing Xia, Bao-Feng Jin, Wei-Hua Li, Tao Li, Bing Liang, Liang Chen, Wei-Li Gong, Ming Yu, Ai-Ling Li, Tao Zhou, Hui-Yan Li.   

Abstract

Janus kinase 1/signal transducers and activators of transcription 3 (JAK1/STAT3) pathway is one of the recognized oncogenic signaling pathways that frequently overactivated in a variety of human tumors. Despite rapid progress in elucidating the molecular mechanisms of activation of JAK/STAT pathway, the processes that regulate JAK/STAT deactivation need to be further clarified. Here we demonstrate that CUE domain-containing 2 (CUEDC2) inhibits cytokine-induced phosphorylation of JAK1 and STAT3 and the subsequent STAT3 transcriptional activity. Further analysis by a yeast two-hybrid assay showed that CUEDC2 could engage in a specific interaction with a key JAK/STAT inhibitor, SOCS3 (suppressors of cytokine signaling 3). The interaction between CUEDC2 and SOCS3 is required for the inhibitory effect of CUEDC2 on JAK1 and STAT3 activity. Additionally, we found CUEDC2 functions collaboratively with SOCS3 to inhibit JAK1/STAT3 signaling by increasing SOCS3 stability via enhancing its association with Elongin C. Therefore, our findings revealed a new biological activity for CUEDC2 as the regulator of JAK1/STAT3 signaling and paved the way to a better understanding of the mechanisms by which SOCS3 has been linked to suppression of the JAK/STAT pathway.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22084247      PMCID: PMC3249090          DOI: 10.1074/jbc.M111.276832

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

1.  Regulation of STAT3-mediated signaling by LMW-DSP2.

Authors:  Y Sekine; S Tsuji; O Ikeda; N Sato; N Aoki; K Aoyama; K Sugiyama; T Matsuda
Journal:  Oncogene       Date:  2006-04-24       Impact factor: 9.867

2.  Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling.

Authors:  A Pezet; H Favre; P A Kelly; M Edery
Journal:  J Biol Chem       Date:  1999-08-27       Impact factor: 5.157

3.  Stat3 as an oncogene.

Authors:  J F Bromberg; M H Wrzeszczynska; G Devgan; Y Zhao; R G Pestell; C Albanese; J E Darnell
Journal:  Cell       Date:  1999-08-06       Impact factor: 41.582

4.  The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families.

Authors:  T Kamura; S Sato; D Haque; L Liu; W G Kaelin; R C Conaway; J W Conaway
Journal:  Genes Dev       Date:  1998-12-15       Impact factor: 11.361

5.  Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line.

Authors:  Waraporn Komyod; Markus Böhm; Dieter Metze; Peter C Heinrich; Iris Behrmann
Journal:  Mol Cancer Res       Date:  2007-03       Impact factor: 5.852

6.  Physical and functional interactions between Daxx and STAT3.

Authors:  R Muromoto; K Nakao; T Watanabe; N Sato; Y Sekine; K Sugiyama; K Oritani; K Shimoda; T Matsuda
Journal:  Oncogene       Date:  2006-03-30       Impact factor: 9.867

7.  Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain.

Authors:  A Sasaki; H Yasukawa; A Suzuki; S Kamizono; T Syoda; I Kinjyo; M Sasaki; J A Johnston; A Yoshimura
Journal:  Genes Cells       Date:  1999-06       Impact factor: 1.891

8.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

9.  CIS3 and JAB have different regulatory roles in interleukin-6 mediated differentiation and STAT3 activation in M1 leukemia cells.

Authors:  R Suzuki; H Sakamoto; H Yasukawa; M Masuhara; T Wakioka; A Sasaki; K Yuge; S Komiya; A Inoue; A Yoshimura
Journal:  Oncogene       Date:  1998-10-29       Impact factor: 9.867

10.  CUE domain containing 2 regulates degradation of progesterone receptor by ubiquitin-proteasome.

Authors:  Pei-Jing Zhang; Jie Zhao; Hui-Yan Li; Jiang-Hong Man; Kun He; Tao Zhou; Xin Pan; Ai-Ling Li; Wei-Li Gong; Bao-Feng Jin; Qing Xia; Ming Yu; Bei-Fen Shen; Xue-Min Zhang
Journal:  EMBO J       Date:  2007-03-08       Impact factor: 11.598

View more
  14 in total

1.  CUE domain-containing protein 2 promotes the Warburg effect and tumorigenesis.

Authors:  Xiuying Zhong; Shengya Tian; Xiang Zhang; Xinwei Diao; Fangting Dong; Jie Yang; Zhaoyong Li; Linchong Sun; Lin Wang; Xiaoping He; Gongwei Wu; Xin Hu; Lihua Wang; Libing Song; Huafeng Zhang; Xin Pan; Ailing Li; Ping Gao
Journal:  EMBO Rep       Date:  2017-03-21       Impact factor: 8.807

2.  Phosphorylation-triggered CUEDC2 degradation promotes UV-induced G1 arrest through APC/C(Cdh1) regulation.

Authors:  Wei-Na Zhang; Jie Zhou; Tao Zhou; Ai-Ling Li; Na Wang; Jin-Jing Xu; Yan Chang; Jiang-Hong Man; Xin Pan; Tao Li; Wei-Hua Li; Rui Mu; Bing Liang; Liang Chen; Bao-Feng Jin; Qing Xia; Wei-Li Gong; Xue-Min Zhang; Li Wang; Hui-Yan Li
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

3.  MicroRNA hsa-miR-324-5p Suppresses H5N1 Virus Replication by Targeting the Viral PB1 and Host CUEDC2.

Authors:  Ashish Kumar; Akhilesh Kumar; Harshad Ingle; Sushil Kumar; Richa Mishra; Mahendra Kumar Verma; Debasis Biswas; Nachimuthu Senthil Kumar; Anamika Mishra; Ashwin Ashok Raut; Akinori Takaoka; Himanshu Kumar
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

4.  CUEDC2 down-regulation is associated with tumor growth and poor prognosis in lung adenocarcinoma.

Authors:  Longhua Sun; Lihong Bai; Gengpeng Lin; Ran Wang; Yangli Liu; Jinghuang Cai; Yubiao Guo; Zhiwen Zhu; Canmao Xie
Journal:  Oncotarget       Date:  2015-08-21

5.  SHP2, SOCS3 and PIAS3 Expression Patterns in Medulloblastomas: Relevance to STAT3 Activation and Resveratrol-Suppressed STAT3 Signaling.

Authors:  Cong Li; Hong Li; Peng Zhang; Li-Jun Yu; Tian-Miao Huang; Xue Song; Qing-You Kong; Jian-Li Dong; Pei-Nan Li; Jia Liu
Journal:  Nutrients       Date:  2016-12-27       Impact factor: 5.717

6.  Interaction of suppressor of cytokine signalling 3 with cavin-1 links SOCS3 function and cavin-1 stability.

Authors:  Jamie J L Williams; Nasser Alotaiq; William Mullen; Richard Burchmore; Libin Liu; George S Baillie; Fred Schaper; Paul F Pilch; Timothy M Palmer
Journal:  Nat Commun       Date:  2018-01-12       Impact factor: 14.919

7.  CUEDC2 suppresses glioma tumorigenicity by inhibiting the activation of STAT3 and NF-κB signaling pathway.

Authors:  Feng Li; Chuanxi Tang; Dan Jin; Li Guan; Yue Wu; Xinfeng Liu; Xiuxiang Wu; Qing Yun Wu; Dianshuai Gao
Journal:  Int J Oncol       Date:  2017-05-17       Impact factor: 5.650

8.  The ubiquitin ligase TRAF6 negatively regulates the JAK-STAT signaling pathway by binding to STAT3 and mediating its ubiquitination.

Authors:  Juncheng Wei; Yanzhi Yuan; Chaozhi Jin; Hui Chen; Ling Leng; Fuchu He; Jian Wang
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

9.  miR-455-5p promotes cell growth and invasion by targeting SOCO3 in non-small cell lung cancer.

Authors:  Junfeng Wang; Yanbo Wang; Dawei Sun; Jianlong Bu; Fenghai Ren; Benkun Liu; Shibo Zhang; Zigeng Xu; Sainan Pang; Shidong Xu
Journal:  Oncotarget       Date:  2017-11-20

10.  CUEDC2, a novel interacting partner of the SOCS1 protein, plays important roles in the leukaemogenesis of acute myeloid leukaemia.

Authors:  Qing-Yun Wu; Yuan-Yuan Zhu; Yang Liu; Fang Wei; Yu-Xue Tong; Jiang Cao; Ping Zhou; Ming-Shan Niu; Zhen-Yu Li; Ling-Yu Zeng; Feng Li; Kai-Lin Xu
Journal:  Cell Death Dis       Date:  2018-07-10       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.